Novo Nordisk 2012 award winning report

Bringing its total to eight first place awards, Novo Nordisk was honoured for having the Best Integrated Report and for demonstrating Credibility Through Assurance for the company’s 2012 Annual Report. The awards were announced at the Corporate Register Reporting Awards (CRRA) in London on 15 May.

See the complete list of 2014 award winners

The CRRA are the only global online reporting awards given annually to identify and acknowledge the best in corporate non-financial reporting. Novo Nordisk has won eight awards since the CRRA were first given in 2007. The company started integrating annual financial and non-financial performance in 2004 to reflect the company’s Triple Bottom Line business principle of balancing profitability with longer-term societal interests.

“Novo Nordisk is helping to improve care for the millions of people living with diabetes. To do this sustainably, we need to know how we are performing, where we’re succeeding and where the challenges are,” says Susanne Stormer, vice president, Corporate Sustainability, Novo Nordisk. “Integrating financial and non-financial reporting, and doing this in a way that is credible, is a valuable way to do this.”

Novo Nordisk’s report was also the 1st runner-up for the Creativity in Communication award. Other top placing companies included Coca Cola and the Co-operative Group as having the Best Report and reporting Relevance and Materiality, respectively.

The Corporate Register Reporting Awards are given based on internet voting results involving approximately 40,000 registered CorporateRegister.com users. The 2014 Corporate Register Reporting Awards was open to reports published between September 2012 and September 2013.

Have a look at Novo Nordisk’s award winning 2012 Annual Report

About Novo Nordisk
Headquartered in Denmark, Novo Nordisk is a global healthcare company with 90 years of innovation and leadership in diabetes care. The company also has leading positions within haemophilia care, growth hormone therapy and hormone replacement therapy. Novo Nordisk employs approximately 40,000 employees in 75 countries, and markets its products in more than 180 countries.

Novo Nordisk strives to conduct its activities in a financially, environmentally and socially responsible way. The strategic commitment to corporate sustainability has brought the company onto centre stage as a leading player in today’s business environment, recognised for its integrated reporting, stakeholder engagement and consistently high sustainability performance.

Novo Nordisk

Novo Nordisk

Novo Nordisk is a global healthcare company with more than 90 years of innovation and leadership in diabetes care. The company also has leading positions within haemophilia care, growth hormone therapy and hormone replacement therapy. We believe that a healthy economy, environment and society are fundamental to long-term value creation. This is why we manage our business in accordance with the Triple Bottom Line business principle and consider the financial, environmental and social impact of our business decisions. The strategic commitment to corporate sustainability has brought the company onto centre stage as a leading player in today's business environment, recognised for its integrated reporting, stakeholder engagement and consistently high sustainability performance.

More from Novo Nordisk